📰 Andreas Bergmann News
Andreas Bergmann News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Andreas Bergmann. Real-time updates on events, politics, business and more.
August 26, 2022
Acute kidney injury (AKI) is a complex syndrome, which results in a rapid loss of kidney function, affecting 1 in 5 patients (1) during hospitalization.Four units at the University Hospital Heidelberg
August 26, 2022
Interdepartmental testing of the kidney function biomarker penKid in routine care at Heidelberg University Hospital and the Heidelberg Kidney Center- Acute kidney injury (AKI) is a complex syndrome, which results in a rapid loss of kidney function, affecting 1 in 5 patients (1) during hospitalization.- Four units at...
August 8, 2022
Issuer: SphingoTec GmbH / Key word(s): Conference Medical thought leaders in critical care aim to advance precision medicine using biomarker-based approaches 08.08.2022 / 10:00 The issuer is solely responsible for the content of this announcement. • Innovative biomarkers open new avenues for ...
August 8, 2022
08.08.2022 Medical thought leaders in critical care aim to advance precision medicine using biomarker-based approaches | acute kidney injury | bio-ADM
May 27, 2022
Shipping company Elbe-Ems has ordered a second Combi Freighter 3850 (CF 3850) from Damen Shipyards, following very positive experience with the vessel of the same type that they ordered before. The first, motor vessel Sophie is operating in European waters since September last year. The second, MV Jan Laurenz will be delivered in the fourth ...
May 18, 2022
Though scientists don’t yet know much about it, a newly described process called erebosis might have profound implications for how the gut maintains itself.
April 14, 2022
A multi-centre study led by the University Hospital Hamburg-Eppendorf (UKE) is evaluating one of the first personalised approaches for moderate to sever...
April 11, 2022
A multi-center study led by UKE is evaluating one of the first personalized approaches for moderate to severe COVID-19 patients.The innovative biomarkers bio-ADM and DPP3 are guiding the enrollment of
April 11, 2022
Issuer: 4TEEN4 Pharmaceuticals GmbH / Key word(s): Study 11.04.2022 / 11:00 The issuer is solely responsible for the content of this announcement. Dipeptidyl Peptidase 3 release is
April 11, 2022
11.04.2022 Biomarker-guided trial led by University Hospital Hamburg-Eppendorf (UKE) opens new avenues for personalized medicine in COVID-19 | bio-ADM | biomarkers | COVID-19 | DPP3